AU2022267220A1 - Substituted amide macrocyclic compounds with orexin-2 receptor agonist activity - Google Patents

Substituted amide macrocyclic compounds with orexin-2 receptor agonist activity Download PDF

Info

Publication number
AU2022267220A1
AU2022267220A1 AU2022267220A AU2022267220A AU2022267220A1 AU 2022267220 A1 AU2022267220 A1 AU 2022267220A1 AU 2022267220 A AU2022267220 A AU 2022267220A AU 2022267220 A AU2022267220 A AU 2022267220A AU 2022267220 A1 AU2022267220 A1 AU 2022267220A1
Authority
AU
Australia
Prior art keywords
formula
another embodiment
ring
alkylene
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2022267220A
Other languages
English (en)
Inventor
Brian M. Aquila
Jörg Martin BENTZIEN
Younggi Choi
Michael R. Hale
Yuan HU
Hoan Huynh
Jonathan Ward LEHMANN
Ingo Andreas Mugge
Lewis D. PENNINGTON
Brian Kenneth Raymer
Roman A. VALIULIN
James R. Woods
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alkermes Inc
Original Assignee
Alkermes Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alkermes Inc filed Critical Alkermes Inc
Publication of AU2022267220A1 publication Critical patent/AU2022267220A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/14—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
AU2022267220A 2021-04-26 2022-04-25 Substituted amide macrocyclic compounds with orexin-2 receptor agonist activity Pending AU2022267220A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163179616P 2021-04-26 2021-04-26
US63/179,616 2021-04-26
PCT/US2022/026144 WO2022232025A1 (en) 2021-04-26 2022-04-25 Substituted amide macrocyclic compounds with orexin-2 receptor agonist activity

Publications (1)

Publication Number Publication Date
AU2022267220A1 true AU2022267220A1 (en) 2023-10-19

Family

ID=81750587

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2022267220A Pending AU2022267220A1 (en) 2021-04-26 2022-04-25 Substituted amide macrocyclic compounds with orexin-2 receptor agonist activity

Country Status (8)

Country Link
US (1) US20240124485A1 (https=)
EP (1) EP4329877B1 (https=)
JP (1) JP2024516633A (https=)
CN (1) CN117440955A (https=)
AU (1) AU2022267220A1 (https=)
CA (1) CA3215210A1 (https=)
ES (1) ES3062687T3 (https=)
WO (1) WO2022232025A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4622712A1 (en) * 2022-11-23 2025-10-01 Vertex Pharmaceuticals Incorporated Substituted macrocyclic amine modulators of orexin receptor 2
KR20250139869A (ko) 2023-01-31 2025-09-23 재즈 파마슈티칼즈 아일랜드 리미티드 거대환식 오렉신 수용체 효능제 및 이의 용도
PE20252742A1 (es) 2023-03-16 2025-12-05 Takeda Pharmaceuticals Co Compuestos heterociclicos macrociclicos y sus usos
IL324946A (en) 2023-06-01 2026-01-01 H Lundbeck As Spiro-macrocyclic orexin 2 receptor agonists
WO2025096445A1 (en) 2023-10-30 2025-05-08 Alkermes, Inc. Synthesis of intermediates for the preparation of macrocyclic compounds
WO2025124698A1 (en) 2023-12-12 2025-06-19 Idorsia Pharmaceuticals Ltd Aryl sulfone and sulfanone derivatives as orexin receptor modulators
TW202542165A (zh) 2023-12-19 2025-11-01 瑞士商愛杜西亞製藥有限公司 大環食慾素激動劑
WO2026017128A1 (zh) * 2024-07-17 2026-01-22 江苏恩华药业股份有限公司 作为食欲素受体激动剂的环烯烃衍生物及其组合物和用途

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AP1542A (en) * 1999-04-30 2006-01-31 Pfizer Prod Inc Glucocorticoid receptor modulators.
EP2038255A2 (en) * 2006-06-16 2009-03-25 High Point Pharmaceuticals, LLC Pharmaceutical use of substituted piperidine carboxamides
US8258163B2 (en) 2008-06-04 2012-09-04 Board Of Regents, The University Of Texas System Small-molecule agonists for type-2 orexin receptor
JP5635991B2 (ja) * 2008-10-30 2014-12-03 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． イソニコチンアミドオレキシン受容体アンタゴニスト
NZ592705A (en) * 2008-12-10 2013-02-22 Achillion Pharmaceuticals Inc 4-amino-4-oxobutanoyl peptide cyclic analogues, inhibitors of viral replication
WO2014198880A1 (en) 2013-06-14 2014-12-18 Ferrer Internacional, S.A. 2-(2-aminophenoxy)-3-chloronaphthalene-1,4-dione compounds having orexin 2 receptor agonist activity
WO2015048091A1 (en) 2013-09-24 2015-04-02 The Board Of Regents Of The University Of Texas System Orexin-control of bone formation and loss
EP3068783B1 (en) 2013-11-15 2020-09-23 The Board of Trustees of the Leland Stanford Junior University Agonists of hypocretin receptor 2 for use for treating heart failure
PE20161064A1 (es) 2013-12-12 2016-10-28 Univ Tsukuba Derivado de sulfonamida o sales de adicion de acido farmaceuticamente aceptables del mismo
WO2015147240A1 (ja) 2014-03-28 2015-10-01 国立大学法人筑波大学 敗血症の予防治療剤
LT3984994T (lt) * 2016-02-04 2024-10-10 Takeda Pharmaceutical Company Limited Pakeistas piperidino junginys kaip 2 tipo oreksino agonistas narkolepsijai gydyti
US11059780B2 (en) * 2017-03-08 2021-07-13 Takeda Pharmaceutical Company Limited Substituted pyrrolidine compound and use thereof
US10428023B2 (en) 2017-08-03 2019-10-01 Takeda Pharmaceutical Company Limited Heterocyclic compound and use thereof
EA039459B1 (ru) * 2017-12-25 2022-01-28 Такеда Фармасьютикал Компани Лимитед Гетероциклическое соединение и его применение в качестве средства для лечения заболеваний, связанных с рецептором орексина 2 типа
JP7339250B2 (ja) * 2018-06-29 2023-09-05 武田薬品工業株式会社 複素環化合物およびその用途
US12312332B2 (en) * 2019-08-08 2025-05-27 Merck Sharp & Dohme Llc Heteroaryl pyrrolidine and piperidine orexin receptor agonists
EP4065585B1 (en) * 2019-11-25 2025-08-20 Alkermes, Inc. Substituted macrocyclic compounds and related methods of treatment
US12006330B2 (en) * 2020-12-21 2024-06-11 Alkermes, Inc. Substituted macrocyclic compounds and related methods of treatment

Also Published As

Publication number Publication date
JP2024516633A (ja) 2024-04-16
CA3215210A1 (en) 2022-11-03
US20240124485A1 (en) 2024-04-18
CN117440955A (zh) 2024-01-23
EP4329877C0 (en) 2026-02-04
EP4329877B1 (en) 2026-02-04
ES3062687T3 (en) 2026-04-13
WO2022232025A1 (en) 2022-11-03
EP4329877A1 (en) 2024-03-06

Similar Documents

Publication Publication Date Title
EP4329877B1 (en) Substituted amide macrocyclic compounds with orexin-2 receptor agonist activity
US12006330B2 (en) Substituted macrocyclic compounds and related methods of treatment
US12441710B2 (en) Substituted piperidino compounds and related methods of treatment
IL320038A (en) Substituted macrocyclic compounds compositions comprising same and uses thereof
AU2022281345A1 (en) Substituted fused bicyclic macrocyclic compounds and related methods of treatment
EP4347604B1 (en) Substituted carbamate macrocyclic compounds and related methods of treatment
AU2023286426A1 (en) Substituted pyrrolidinyl and piperidinyl compounds and related methods of treatment
WO2023249872A1 (en) Substituted fused bicyclic compounds and related methods of treatment
HK40099265B (en) Substituted piperidino compounds and related methods of treatment
HK40099265A (en) Substituted piperidino compounds and related methods of treatment
AU2023289631A1 (en) Substituted fused bicyclic compounds and related methods of treatment